Search

Displaying results 4711 - 4720 of 5897 in total
  1. Drug

    Eftansomatropin alfa

    go.drugbank.com/drugs/DB18460
    Investigational

    Eftansomatropin alfa (GX-H9) comprises a recombinant human growth hormone fused to hyFc, a synthetic hybrid Fc fragment.

  2. Drug

    Pegilodecakin

    go.drugbank.com/drugs/DB15162
    Investigational

    Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small

  3. Drug

    Lulizumab pegol

    go.drugbank.com/drugs/DB15441
    Investigational

    Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).

  4. Drug

    Gontivimab

    go.drugbank.com/drugs/DB16179
    Investigational

    Gontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus

  5. Drug

    Survodutide

    go.drugbank.com/drugs/DB18989
    Investigational

    Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT

  6. Drug

    AZD8630

    go.drugbank.com/drugs/DB19397
    Investigational

    AZD8630 is an experimental drug under investigation, as described in the Phase I clinical study titled "Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics

  7. Drug

    Uproleselan

    go.drugbank.com/drugs/DB14829
    Investigational

    Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy

  8. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult. … KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting

  9. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis.

    Synonyms: (2′S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2′-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5′,6-dimethyl[1(2H),4′-bipyridin]-2-one, (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one
  10. Drug

    LGD-6972

    go.drugbank.com/drugs/DB14779
    Investigational

    LGD-6972 is under investigation in clinical trial NCT01919684 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes